Oral tranexamic acid for the treatment of melasma: evidence and experience-based consensus statement from Indian experts

Melasma, a chronic pigmentary skin condition mainly affecting the face, remains a challenge despite the availability of several options for treatment. Many melasma patients are not satisfied with treatment outcomes. Tranexamic acid (TXA), an anti-fibrinolytic drug has shown promising results in pati...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of dermatology 2023-03, Vol.68 (2), p.178-185
Main Authors: Godse, Kiran, Sarkar, Rashmi, Mysore, Venkataram, Shenoy, Manunath, Chatterjee, Manas, Damisetty, Rajetha, Shah, Swapnil, Vedamurthy, Maya, Aurangabadkar, Sanjeev, Srinivas, Chakravarthi, Ganjoo, Anil, Das, Sudip, Patil, Anant
Format: Article
Language:English
Subjects:
adverse event
anti-fibrinolytic agent
Antifibrinolytic agents
Care and treatment
evidence
Face
Fluocinolone
Fluocinolone acetonide
Medical research
Medicine, Experimental
Melanosis
Pigments
Review
Skin diseases
Tranexamic acid
treatment outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Melasma, a chronic pigmentary skin condition mainly affecting the face, remains a challenge despite the availability of several options for treatment. Many melasma patients are not satisfied with treatment outcomes. Tranexamic acid (TXA), an anti-fibrinolytic drug has shown promising results in patients with melasma. Evidence from several clinical studies has surfaced on efficacy and tolerability of TXA in these patients. It can be used as monotherapy or adjuvant with other therapies. Currently, there is no published consensus or guideline document for its use in the treatment of melasma. TXA is available for oral use, topical use as well as an injection. In this article, a consensus of Indian experts is prepared based on the available literature and experience with use of oral TXA in melasma. This review article might help clinicians for use of oral TXA appropriately while treating melasma.
ISSN:0019-5154
1998-3611
DOI:10.4103/ijd.ijd_266_22